Ionis Pharmaceuticals Looks Undervalued - Q4, FY Earnings Will Be Important [Seeking Alpha]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Seeking Alpha
Summary Ionis has been a major player in RNA-based therapeutics for a long time. The company is partnered with numerous big-pharma companies developing a range of drugs to treat neurology, liver and cardiovascular diseases ranging from rare to ultra-rare. Of its 3 commercialised drugs, Spinraza delivers consistent quarterly revenues of ~$80m but Tegsedi may struggle and Waylivra (approved in Europe) is unproven. The company's share price has barely moved in 1 year whilst other RNA drug-developers have experienced large gains. As such the stock appears to be undervalued and although there are caveats, an investment before FY results are announced could pay off nicely if management hit targets of $1bn in sales. Investment Thesis I have been looking at biotech stocks that are developing RNA-based therapies - both anti sense and RNA interference (RNAi) - or have commercialised drugs using this form of therapy. Ionis Pharmaceuticals ( IONS My research indicates that Ionis is a somewhat eni
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Piper Sandler from $65.00 to $62.00. They now have an "overweight" rating on the stock.MarketBeat
- Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Company News for Nov 7, 2024 [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $82.00 to $77.00. They now have an "overweight" rating on the stock.MarketBeat
IONS
Earnings
- 11/6/24 - Beat
IONS
Sec Filings
- 11/13/24 - Form 144/A
- 11/12/24 - Form 144
- 11/12/24 - Form 144
- IONS's page on the SEC website